Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osocimab
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Osocimab is a fully human monoclonal IgG1 antibody that acts as a selective inhibitor of activated coagulation factor XI (factor XIa). Developed using phage display technology, it binds directly and specifically to a region adjacent to the FXIa active site, inhibiting its activity through an allosteric mechanism. Osocimab is being investigated primarily for anticoagulation in patients at risk of thromboembolic events, such as those undergoing orthopedic surgery or with kidney failure on hemodialysis. It has demonstrated dose-dependent prolongation of activated partial thromboplastin time (aPTT) and is associated with a low risk of bleeding in clinical trials. The drug was developed by Bayer[2][3][4][6][7].
- Other names
- FXIa antibody
02
Targets
Factor XIa
Beyond the preview
Go deeper on osocimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osocimab.